In this issue, Sorbara et al. (2014) demonstrate that axonal transport impairment is an early feature of neurodegeneration in multiple sclerosis models. This transport deficit is reversible by anti-inflammatory intervention but, if untreated, can contribute to late-stage axonal dystrophy.
Multiple sclerosis (MS) is the most common, chronic disabling neuroinflammatory condition affecting young adults. The clinical manifestations of MS are variable but include motor dysfunction, sensory and visual impairment, and neuropsychological problems. Following the first attack the disease course typically comprises periods of relapse and remission. Approximately 50%-65% of patients then go on to develop secondary progressive disease, with progressive neurological decline without definite remission between the acute relapses. Ten to twenty percent of patients have primary progressive MS and show no remission after the first attack, instead displaying progressive decline from the outset. Regardless of the exact MS subtype, neurological decline is inevitable and, within 25 years post diagnosis, about half of patients require the permanent use of a wheelchair (Compston and Coles, 2008) . A recent study by Sorbara et al. (2014) now explores how the neurodegeneration that is common to all MS patients and that directly drives disability is promoted by deficits in axonal transport-a key process for the maintenance of axonal homeostasis and function.
The precise pathophysiological mechanisms that cause MS remain to be fully elucidated. However, the disease is considered to be an autoimmune condition initiated by auto-reactive immune cells that cross the blood-brain barrier and target the central nervous system (CNS). The inflammatory infiltrate leads to the formation of lesions that are a key disease feature and are characterized by the presence of immune cells, demyelinated axons, lower oligodendrocyte numbers, transected axons, and glial hypertrophy. The infiltration eventually promotes continued activation of macrophages that home to the CNS and of resident microglia, thereby further disseminating the inflammation and ensuing demyelination and neuroaxonal damage. Gradually, the neurodegenerative process becomes self-perpetuating, resulting in irreversible disability (Compston and Coles, 2008; Fugger et al., 2009; Friese et al., 2014) .
The immunological component is the best understood etiopathological aspect of MS, and its importance in the disease has been emphasized by the findings of large-scale genetic analyses (Beecham et al., 2013) , the identification of EpsteinBarr virus as an environmental contributor to MS (Sundqvist et al., 2012) , and animal model studies in which the MS-like disease experimental autoimmune encephalomyelitis (EAE) can be induced through immune activation (Fugger et al., 2009 ). The appreciation of immune dysfunction as a driver of MS development has had a catalytic effect clinically: two decades ago, the disease was only poorly treated and there were no medications prescribed to specifically treat MS, but today there are some ten different immunomodulatory drugs (IMDs) available (Figure 1 ). However, despite this progress, these IMDs have varying efficacy and are associated with a number of unwanted side effects ranging from flu-like symptoms to malignancies and even fatal opportunistic infections (Bloomgren et al., 2012) . Furthermore, even if they reduce relapses, none of the IMDs ultimately prevent or halt neurodegeneration.
The implications of this clinical outcome are two-fold. First, it is now apparent that there is an unmet need for novel therapeutic strategies that can specifically target neurodegeneration, shifting the balance toward reduced neuroaxonal damage and increased neuroprotection and/or regeneration. Second, although CNS damage in MS may be initiated by the inflammatory infiltrate, neurodegeneration should not be considered as the second phase of the disease but as an early, concomitant process that is already underway by the time of clinical diagnosis (Friese et al., 2014) . The conceptual uncoupling of neuroaxonal degeneration from the classical sequential view of MS disease course progression has spurred research to try to fill in the gaps in our understanding of the molecular and cellular mechanisms that cause the degeneration. Axonal injury is a critical event: axonal damage can be detected even in MS lesion axons that are still myelinated (Niki c et al., 2011) , and axonal loss perhaps provides the best correlate of the neurological disability seen in the disease. Although the more traditional methodologies, such as CNS tissue immunohistochemistry, have provided some information regarding the pathogenic features of axonal injury, the interrogation of the dynamics of axonal dysfunction has necessitated technological advances such as the use of in vivo two-photon imaging (Misgeld and Kerschensteiner, 2006) . The paper by Sorbara et al. (2014) employs this technique to investigate the potential role of impaired axonal transport in MS neurodegeneration by directly assaying organelle trafficking and microtubule stability along individual spinal axons following EAE induction.
Axonal transport is the process by which cargo shuttles long distances between the neuronal cell body and synapses along the axon; it is essential to neuronal function and allows axons to be supplied with lipids, proteins, and organelles from the soma (through anterograde transport), while components that require degradation or recycling are trafficked back to the cell body (through retrograde transport). Axonal transport impairment has been described in the more classical neurodegenerative diseases, but Sorbara et al. (2014) now demonstrate that it is also a prominent feature of neuroinflammatory lesions in MS-like disease. Using mice in which the transport of single, fluorescently-labeled organelles (mitochondria in Thy1-MitoCFP mice and peroxisomes in Thy1-PeroxiYFP animals) can be tracked along the spinal axons in vivo, the authors compared transport in the healthy as opposed to inflamed spinal cord. Intriguingly, they found that transport was not only reduced in the degenerating axons but also in the majority of normal-appearing axons found in the lesions, indicating that transport disturbances may promote and demarcate the more pervasive axonal dysfunction that precedes progressive degeneration. Notably, the localized transport deficits were detected acutely but also persisted for a number of weeks in a chronic EAE model. A net deficiency of organelle delivery from the cell body to the synapses was observed as anterograde rather than retrograde transport was more significantly affected. This also coincided with organelle arrest in areas of neuroinflammation such that mitochondrial 
MS Drugs and the Spatial Distribution of Their Respective Targets
The majority of drugs available for MS or in clinical trials are immunomodulatory. While the exact mechanisms of action of many of these therapeutics have not been fully elucidated, they can be broadly categorized into those that prevent the immune cell egress from secondary lymphoid organs (fingolimod), those that regulate peripheral immune cell activation (e.g., IFNb, daclizumab), those that prevent immune cells from crossing the blood-brain barrier (natalizumab), and those that are thought to further suppress inflammation in the CNS (e.g., laquinimod). By comparison, there is a striking lack of non-immunological drug targets within the CNS, with perhaps the exception of axonal ion channels that become redistributed and dysfunctional upon axonal damage. Abbreviations are as follows: APC, antigen-presenting cell; ASIC1, acid-sensing ion channel 1; B, B lymphocyte; BDNF, brain-derived neurotrophic factor; DC, dendritic cell; DMF, dimethyl fumarate; GLAT, glatiramer acetate; IFNb, type I interferon-beta; IL-10, interleukin-10; NK, natural killer lymphocyte; ODC, oligodendrocyte; PC, plasma cell; T, T lymphocyte; Th1, T helper lymphocyte type 1; Th2, T helper lymphocyte type 2; Th17, T helper lymphocyte type 17; S1PR, sphingosine-1-phosphate receptor; and VCAM1, vascular cell adhesion molecule 1. accumulation, for example, was observed within the lesions.
To better comprehend the mechanism underpinning this impaired mitochondrial transport, the authors determined whether or not damage to mitochondria, which has been previously described in lesions (Niki c et al., 2011) , might contribute to the observed deficit-especially as axonal transport itself is highly energy demanding. However, there was no correlation between altered mitochondrial morphology and impaired transport rates. Microtubule stability was also assessed, given the role of this cytoskeletal component as a dynamic platform for trafficking along axons, using quantitative immunohistochemistry for stabilization status markers, and electron microscopy and in vivo two-photon imaging with Thy1-EB3-YFP mice to assay microtubule orientation. The transport deficits were observed prior to the marked microtubule destabilization detectable in the swollen axons found in lesions. This is consistent with transport impairment occurring in normal-appearing as well as degenerating axons running through lesions and perhaps also suggests that microtubule destabilization marks more permanent structural axon damage. Finally, the establishment of axonal transport deficiency as an early phenomenon in the development of progressive axonal dystrophy led Sorbara et al. (2014) to hypothesize that this deficit could be reversed in axons that did not show prominent structural damage: such a reversal was noted as acute disease subsided but also following the administration of anti-inflammatory and anti-oxidative interventions.
A challenge now is to determine how closely the characteristics of axonal transport deficits observed in models of MS correspond to the human disease, but studies such as that by Sorbara et al. (2014) will help to more accurately delineate the temporal relationship between the perceived cascade of sequelae that are instigated by CNS inflammation and that ultimately lead to neurodegeneration. This is particularly critical: to date, only a few potential neuronal drug targets-chiefly ion channels-have been identified for MS (Figure 1 ; summarized by Friese et al., 2014) , but with the advent of more tractable high-throughput screening approaches (Mei et al., 2014) and stem cell technology-related advances in our understanding of neuro-restorative pathways (Yang et al., 2013) , the eventual discovery of additional putative targets is anticipated. However, for the benefits of such therapeutic manipulation to be maximized, the window of opportunity must be defined so that the progressive, long-term neurodegenerative processes to be targeted can be dissociated from shorter-term events that may already be indirectly rectified by the action of available IMDs. Considering the complexity and chronicity of neurodegeneration in MS, a combinatorial treatment approach may very well be required to keep inflammation at bay, dampen down and contain neuroaxonal damage and death, boost defensive mechanisms, and promote remyelinaton and repair.
